Etanercept-induced lichenoid reaction pattern in psoriasis

Journal of Dermatological Treatment

Volumn 17, Issue 6, 2006, Pages 381-383

  Bovenschen, Jorn H ^a,b   Kop, Else N ^a   Van De Kerkhof, Peter C M ^a   Seyger, Marieke M B ^a  

^a RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anti TNF ; Drug eruption; Etanercept

Indexed keywords

ETANERCEPT;

AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; COURSE EVALUATION; DISEASE SEVERITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERYTHEMATOSQUAMOUS SKIN DISEASE; FEMALE; GENERAL CONDITION IMPROVEMENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LICHENOID ERUPTION; PRIORITY JOURNAL; PSORIASIS; REMISSION; THERAPY EFFECT; TISSUE SECTION; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

AGED; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; LICHENOID ERUPTIONS; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 34250177232     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630600967174     Document Type: Article

References (16)

1. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik S, Wang A, et al. Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014-22.
2. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, et al. EXPRESS study investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial. Lancet. 2000;366:1367-74.
3. Patel T, Gordon KB. Adalimumab: Efficacy and safety in psoriasis and rheumatoid arthritis. Dermatol Ther. 2004;17:427-31.
4. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial. Lancet. 2000;356:385-90.
5. Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL. Dermatological conditions during TNF-blocking therapy in patients with rheumatoid arthritis: A prospective study. Arthritis Res Ther. 2005;7:R666-76.
6. Wright RC. Atopic dermatitis-like eruption precipitated by infliximab. J Am Acad Dermatol. 2003;49:160-1.
7. Vergara G, Silvestre JF, Betlloch I, Vela P, Albares MP, Pascual JC. Cutaneous drug eruption to infliximab: Report of 4 cases with an interface dermatitis pattern. Arch Dermatol. 2002;138:1258-9.
8. Kent PD, Davis JM, Davis MD, Matteson EL. Bullous skin lesions following infliximab infusion in a patient with rheumatoid arthritis. Arthritis Rheum. 2002;46:2257-8.
9. Thielen AM, Kuenzli S, Saurat JH. Cutaneous adverse events of biological therapy for psoriasis: Review of the literature. Dermatology. 2005;211:209-17.
10. Burge D. Etanercept and squamous cell carcinoma. J Am Acad Dermatol. 2003;49:358-9.
11. Bovenschen HJ, Tjioe M, Vermaat H, de Hoop D, Witteman BM, Janssens RW, et al. Induction of eruptive benign melanocytic naevi by immune suppressive agents, including biologicals. Br J Dermatol. 2006;154:880-4.
12. Smith KJ, Skelton HG. Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy. J Am Acad Dermatol. 2001;45:953-6.
13. Bleumink GS, ter Borg EJ, Ramselaar CG, Stricker BHC. Etanercept-induced subacute cutaneous lupus erythematosus. Rheumatology. 2001;40:1317-19.
14. Gillum PS, Golitz LE. Psoriasiform dermatitis. In: Barnhill RL, editor. Textbook of dermatopathology. USA: McGraw-Hill; 1998. p. 55-7.
15. Weedon D, editors, Major tissue reaction patterns. In, Skin pathology. 2nd ed, Elsevier; 2002. p. 4.
16. Weedon D, editors, The lichenoid reaction pattern. In, Skin pathology. 2nd ed, Elsevier; 2002. p. 41.